NCT06793241View on ClinicalTrials.gov

Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

January 31, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells injection

Each subject receive CD19 B-cell Acute Lymphoblastic Leukemia Targeted CAR T-cells by intravenous infusion

Trial Locations (1)

310003

RECRUITING

The first affiliated hospital of medical college of zhejiang university, Hangzhou

All Listed Sponsors
collaborator

Yake Biotechnology Ltd.

INDUSTRY

lead

Zhejiang University

OTHER